权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Engineering Smart Protein Coronas to Advance Theraputic mRNA Delivery

设计智能蛋白冠以推进治疗性 mRNA 传递

基本信息

批准号：
10056170
负责人：
Jilian R Melamed
金额：
$ 6.64万
依托单位：
CARNEGIE-MELLON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-12-01 至 2021-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10056170
关键词：
Apolipoprotein E Asthma Binding Biodistribution Blood Circulation Brain C57BL/6 Mouse Carrier Proteins Cell Surface Receptors Cells Chemistry Clinical Coronary Arteriosclerosis Cytoplasm Data Development Diabetes Mellitus Disease Drug Carriers Drug Kinetics Drug Targeting Elements Engineering FDA approved Face Flow Cytometry Future Genes Genetic Diseases Genetic Translation Heart Hepatocyte Image Cytometry Immune Immunotherapy Injections Knowledge Libraries Library Materials Liver Liver diseases Luciferases Lung Mass Spectrum Analysis Measures Mediating Messenger RNA Molecular Multiple Sclerosis Mus Organ Pancreas Pharmaceutical Preparations Production Property Protein Engineering Proteins Proteomics RNA delivery Receptor Cell Research Research Personnel Reticuloendothelial System Scientific Advances and Accomplishments Serum Serum Proteins Small Interfering RNA Spleen Therapeutic Time Tissues Translating Work cellular targeting clinical translation design efficacy study enzyme replacement therapy gene therapy implantable device improved in vivo in vivo imaging system innovation insight intravenous injection lipid nanoparticle lipid transport mRNA delivery mRNA tagging nano nanocarrier nanoparticle nanoparticle delivery nanoparticle drug nucleic acid delivery receptor recruit small molecule success targeted agent tool vaccine development

项目摘要

While gene therapy with mRNA offers tremendous potential to transform the management of genetic diseases, delivering mRNA outside the reticuloendothelial system (e.g. liver and spleen) remains challenging. Without carriers that can reach organs such as the lungs, heart, brain, or pancreas, the potential of mRNA to treat diseases of those organs, such as asthma, coronary artery disease, multiple sclerosis, and diabetes, will remain untapped. This research will establish the protein corona as a new lipid nanoparticle design element that can be engineered to achieve mRNA delivery outside the reticuloendothelial system. Upon injection into the body, lipid nanoparticles are immediately coated in local proteins, forming a protein corona that interfaces with cells and tissues. The composition of that natural corona has been shown to strongly influence nanoparticle fate in vivo. This work will develop “smart” protein coronas by pre-coating mRNA lipid nanoparticles with proteins that localize to organs outside the reticuloendothelial system prior to administration. In Aim 1, a small library of naturally-occurring proteins will be evaluated for their ability to direct mRNA delivery to non-reticuloendothelial organs, including the lungs, heart, brain, and pancreas, in C57BL/6 mice. Imaging and flow cytometry will be used to identify organ and cellular targets of smart corona-coated mRNA lipid nanoparticles. Aim 2 will elucidate the mechanisms by which smart corona-coated lipid nanoparticles enable differential organ targeting. Smart coronas may enable differential targeting by altering circulation time, by recruiting additional serum proteins that serve as active targeting agents, or by binding specific cell surface receptors via the smart corona itself or via additionally adsorbed proteins. Proteomic analysis will determine what proteins adsorb coated-lipid nanoparticles upon intravenous injection, and cell receptor blocking studies will identify cellular targets that facilitate effective mRNA delivery. This work is innovative in that it will establish the protein corona as a previously-unappreciated nanoparticle design element that can be engineered to enable mRNA delivery to challenging organ targets. While efficacious smart coronas will provide researchers with new tools to advance drug targeting, mechanistic insights will inform future smart corona design. This research is significant because it will contribute a paradigm-shifting targeting strategy to accelerate the clinical translation of mRNA therapeutics for extrahepatocellular diseases. Further, the results obtained by this research will advance the delivery of nucleic acids, small molecules, and proteins from diverse drug carriers, such nanoparticles, drug conjugates, and implantable devices. Ultimately, the knowledge generated by this work has the potential to transform and accelerate the development of targeted drug carriers.

而mRNA的基因治疗为改变遗传疾病的管理提供了巨大的潜力